Hopefully, some novel therapies emerged in recent years, like chimeric antigen receptor-T cell (CAR-T) therapy targeted on EGFR vIII and nanoparticle delivery of EGFR inhibitors, but their real effectiveness in gliomas is yet to be explored (22, 23). This evidence concerns the gene EGFR and glioma.